10 Best Long Term ASX Stocks to Buy Now

8) Immutep Limited (NASDAQ:IMMP)

Number of Hedge Fund Holders: 2

Immutep Limited (NASDAQ:IMMP) is a clinical-stage biotechnology company engaged in developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The company announced positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients. As per Prof. Dr. Salah-Eddin Al-Batran of the Frankfurt Institute of Clinical Cancer Research (IKF) and project lead, the strength of such mature survival results together with a favourable safety profile in first-line treatment of patients with non-squamous NSCLC, the vast majority of whom possess negative or low PD-L1 expression, remains encouraging.

Immutep Limited (NASDAQ:IMMP) has also released its quarterly activities report for Q2 2025. Marking its transition to a Phase III biotech, the company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) got the first regulatory approval. Notably, mature data from INSIGHT-003 in 1L NSCLC exhibits an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, surpassing the historical controls. In another development, the company announced favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. Notably, through the first 3 of 5 single ascending dose cohorts in healthy participants, there were no treatment-related adverse events.